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Summary
 
Little is understood of the anatomical fate of activated T lymphocytes and the consequences
they have on the tissues into which they migrate. Previous work has suggested that damaged
lymphocytes migrate to the liver. This study compares class I versus class II major histocompat-
ibility complex (MHC)–restricted ovalbumin-specific T cell antigen receptor (TCR) trans-
genic mice to demonstrate that after in vivo activation with antigen the emergence of
CD4
 
2
 
CD8
 
2
 
B220
 
1
 
 T cells occurs more frequently from a CD8
 
1
 
 precursor than from CD4
 
1
 
 T
cells. Furthermore, this change in phenotype is conferred only by the high affinity native pep-
tide antigen and not by lower affinity peptide variants. After activation of CD8
 
1
 
 cells with only
the high affinity peptide, there is also a dramatically increased number of liver lymphocytes
with accompanying extensive hepatocyte damage and elevation of serum aspartate transami-
nase. This was not observed in mice bearing a class II MHC–restricted TCR. The findings
show that CD4
 
2
 
CD8
 
2
 
B220
 
1
 
 T cells preferentially derive from a CD8
 
1
 
 precursor after a high
intensity TCR signal. After activation, T cells can migrate to the liver and induce hepatocyte
damage, and thereby serve as a model of autoimmune hepatitis.
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T
 
he activation of lymphocytes is accompanied by nu-
merous changes in surface phenotype. Many of these
changes, such as increased surface LFA-1 and the hyal-
uronate receptor/memory marker CD44, as well as decreased
L-selectin (1), are critical to lymphocyte homing. Lympho-
cyte activation also results in clonal expansion, often fol-
lowed by cell death through Fas-dependent apoptosis (2,
3). In some instances of T lymphocyte apoptosis, there may
be an accompanying change in surface phenotype with
downmodulation of CD4 or CD8 and upregulation of the
B cell isoform of CD45 known as B220 (4, 5).
Collectively, the dynamic alterations in the trafficking of
lymphocytes allow binding to vascular endothelium and the
subsequent egress to extravascular tissues. The fate of lym-
phocytes once they have extravasated into tissues is less well
understood, as are the consequences to the tissues that are in-
filtrated. The liver is a good model system in which to exam-
ine these events, as it contains a significant population of T
cells expressing a previously activated phenotype, including
expression of CD44, and in some instances a significant
proportion of cells manifesting the phenotype CD4
 
2
 
CD8
 
2
 
B220
 
1
 
 TCR-
 
a/b
 
intermediate
 
 (4, 6). The origin of the latter pop-
ulation is unresolved. Some studies have argued that this sub-
set represents a proliferating T cell population whose lineage
is unique to the liver (7), whereas other investigations suggest
that cells of the same phenotype might migrate to the liver af-
ter activation elsewhere, and undergo apoptosis within the
liver (4). The lack of any significant expression of recombina-
tion-activating gene RAG-1 or RAG-2, proteins essential for
rearrangement of the TCR 
 
a
 
 and 
 
b
 
 chains, by murine liver
lymphocytes also argues against the adult liver being a site
of T lymphocyte development (8). A third, although not mu-
tually exclusive, view has shown that a subset of CD4
 
2
 
CD8
 
2
 
and CD4
 
1
 
 T cells that express the natural killer marker
NK1.1 use a highly limited TCR repertoire (V
 
a
 
14, V
 
b
 
8.2,
V
 
b
 
7, or V
 
b
 
2) and are restricted in their response to the
class I–like molecule CD1 (9).
We have previously proposed a model whereby
CD4
 
2
 
CD8
 
2
 
B220
 
1
 
TCR-
 
a/b
 
1
 
 cells result from a high inten-
sity TCR signal that leads in most instances to apoptosis (10).
A large proportion of the precursors of this subset are proba-
bly previously expressed CD8, as reflected by demethylation
of the CD8
 
a
 
 gene in CD4
 
2
 
CD8
 
2
 
TCR-
 
a/b
 
1
 
 cells in the
thymus (11) and periphery (12). The further observation that
mice lacking class I MHC expression are nearly devoid of
CD4
 
2
 
CD8
 
2
 
TCR-
 
a/b
 
1
 
 cells (13–15) suggests that these un-
usual cells require an active signal conferred by class I MHC.
In this study this model has been tested in two different TCR
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transgenic mice that recognize chicken OVA restricted to
either class I MHC (OT-1 mice) or class II MHC (DO.11.10
mice). Our findings demonstrate that after equivalent doses of
the appropriate OVA peptide, only the CD8
 
1
 
 T cells from
OT-1 mice showed increased expression of surface B220,
with a portion becoming CD4
 
2
 
CD8
 
2
 
. The activated CD8
 
1
 
OT-1 T cells also migrated to the liver in considerably higher
numbers and produced more hepatocyte damage than did
activated CD4
 
1
 
 cells in DO.11.10 mice. These findings were
not observed in OT-1 mice that received lower affinity vari-
ants of the native OVA peptide. This suggests a model of
autoimmune hepatitis in which stimulation of the T lympho-
cytes can occur at distant lymphoid sites, with subsequent
migration to the liver where they provoke hepatocyte injury.
 
Materials and Methods
 
Mice.
 
Normal strains of C57BL/6 and BALB/c mice and
transgenic DO.11.10 or OT-1 mice were bred at the animal fa-
cilities of The University of Vermont College of Medicine. Orig-
inal breeding pairs of normal mice were obtained from The Jack-
son Laboratory (Bar Harbor, ME). DO.11.10 TCR transgenic
mice recognize chicken OVA peptide 323–339 in the context of
class II MHC, I-A
 
d
 
, and were the gift of Dr. Dennis Loh (Wash-
ington University, St. Louis, MO; reference 16). DO.11.10 mice
were maintained by breeding transgenic male mice to normal
BALB/c females. Offspring bearing the TCR transgene were
identified by expression of the clonotype TCR identified by mAb
KJ1-26. OT-1 mice bear a transgenic TCR that recognizes
chicken OVA peptide 257–264 restricted to class I MHC, K
 
b
 
,
and were provided by Drs. Francis Carbone (Monash University
Medical School, Victoria, Australia) and Michael Bevan (Univer-
sity of Washington, Seattle, WA; reference 17). OT-1 mice were
maintained by breeding TCR transgenic male mice to normal
C57BL/6 females. Offspring were screened for the clonotype
TCR using anti-V
 
a
 
2 mAb.
 
Antibodies, Cell Preparations, and Flow Cytometry.
 
Monoclo-
nal anti–murine CD8
 
a
 
 conjugated to Red613 and PE-conju-
gated B220 were purchased from Caltag Labs. (Burlingame, CA).
Monoclonal anti–murine CD4 conjugated to Red613 was pur-
chased from GIBCO BRL (Gaithersburg, MD). Monoclonal
anti–murine V
 
a
 
2 conjugated to FITC or PE was purchased from
PharMingen (San Diego, CA). The hybridoma KJ1-26, which
reacts to the clonotype TCR of DO.11.10 mice, was the gift of
Dr. Philippa Marrack (National Jewish Center for Immunology
and Respiratory Diseases, Denver, CO). KJ1-26 was purified
from mouse ascites on HiTRAP Protein G columns (Amersham
Pharmacia Biotech, Inc., Piscataway, NJ), and then conjugated to
fluorescein (Sigma Chemical Co., St. Louis., MO) using estab-
lished methods (18). Fluorescein-conjugated antibody was puri-
fied from reaction components by chromatography on PD-10
columns (Amersham Pharmacia Biotech., Inc.).
Single cell suspensions were made by homogenizing tissues in
RPMI 1640 medium (GIBCO BRL) supplemented with 5%
(vol/vol) bovine calf serum (BCS)
 
1
 
 (Hyclone Laboratories, Lo-
gan, UT). Cells excluding trypan blue were counted. For flow
cytometry, 10
 
6
 
 cells were incubated in 0.1 ml PBS containing
0.5% BSA Fraction V, 0.001% (wt/vol) sodium azide (Sigma
Chemical Co.), and the antibodies listed above (3 
 
m
 
g/ml) at 4
 
8
 
C
for 30 min (PBS azide). After washing with PBS-azide, cells were
fixed in 1% (vol/vol) methanol-free formaldehyde (Ted Pella
Inc., Reading, CA) in PBS-azide. Samples were stored at 4
 
8
 
C
until they were analyzed with a Coulter Elite flow cytometer cal-
ibrated using DNA check beads (Coulter, Inc., Hialeah, FL).
Apoptosis was quantified using staining with FITC-conjugated
Annexin V (Nexins Research B.V., Hoeven, The Netherlands),
which binds to phosphatidylserine residues that are found on the
inner leaflet of cytoplasmic membranes of living cells but trans-
locate to the outer leaflet upon initiation of apoptosis (19). Data
were gated using Elite software by forward and side light scatter.
Negative controls were set by using isotype-matched Ig directly
conjugated to fluorochromes (Caltag Labs.).
 
OVA Peptides and Treatment of TCR Transgenic Mice.
 
Peptides to
chicken OVA 323–339 (ISQAVHAAHAEINEAGR) (OVA
 
II
 
),
257-264 (SIINFEKL) (OVA
 
I
 
), or OVA
 
I
 
 variants E1(EIINFEKL)
and R4 (SIIRFEKL) were produced at Macromolecular Re-
sources (Colorado State University, Fort Collins, CO). OVA
 
I
 
/K
 
b
 
binds to the OT-1 TCR with high affinity (
 
K
 
d
 
 
 
5 
 
6.5 
 
m
 
M),
whereas E1 and R4 bind with lesser affinities of 22.6 and 57.1
 
m
 
M, respectively (20). OVA
 
II
 
/I-A
 
d
 
 binds to the DO.11.10 TCR
with a 
 
K
 
d
 
 of 31 
 
m
 
M (21). Mice received one, two, or three daily
intraperitoneal injections of 250 
 
m
 
l of 100-
 
m
 
M peptide solutions
in PBS or PBS alone. Tissues were harvested 1, 2, 3, 5, or 7 d
after the last injection of peptide.
 
Isolation of Liver Lymphocytes.
 
After death, the peritoneal cavity
was opened and the portal vein was identified. This was cannulated
with a 27-gauge needle and perfused with 5 ml PBS until all the
lobes of the liver blanched. With the needle remaining in the portal
vein, the inferior vena cava was cut above the liver. The liver was
then excised with forceps and the gall bladder was identified and
removed. The liver was washed once in RPMI/5% BCS and then
cut into small pieces and homogenized in a tissue grinder. Cells
were then spun once at 1,200 rpm for 10 min. Supernatant was re-
moved and the cells were resuspended in 10 ml of digestion mix
consisting of serum-free RPMI containing 0.05% collagenase IV
and 0.002% DNAse I (both from Sigma Chemical Co.), and then
they were incubated at 37
 
8
 
C for 40 min, mixing the tube fre-
quently. 30 ml of serum-free RPMI was then added and spun at
300 rpm for 3 min. This sedimented the majority of hepatocytes
but left lymphocytes in the supernatant. The supernatant was trans-
ferred to another 50-ml tube and spun at 1,200 rpm for 10 min.
The supernatant was aspirated and the cells were then resuspended
in a total volume of 1.6 ml serum-free RPMI and transferred to a
15-ml tube. 2.4 ml of 40% (wt/vol) metrizamide (Sigma Chemical
Co.) in PBS was added to the cells and mixed well. This solution
was underlaid with 1 ml serum-free RPMI and spun at 2,500 rpm
for 20 min. Liver lymphocytes were identified at the interface,
carefully aspirated with a pasteur pipette, and transferred to another
15-ml tube, then washed with RPMI/5% BCS and spun at 1,600
rpm for 10 min. Cells were then resuspended in RPMI/5% BCS
for analysis or placed in culture in complete medium (RPMI 1640,
5% FCS, 25 mM Hepes, 292.3 
 
m
 
g/ml glutamine, 2,500 
 
m
 
g/ml
glucose, 10 
 
m
 
g/ml folate, 110.4 
 
m
 
g/ml pyruvate, 5 
 
3 
 
10
 
2
 
5
 
 M
2-ME, 100 U/ml penicillin, and 100 U/ml streptomycin).
 
Results
 
Trafficking of CD8
 
1
 
 T Cells to the Liver Is Induced only by
High Affinity Peptide Antigen.
 
To assess the relative dynam-
 
1
 
Abbreviations used in this paper:
 
 AST, aspartate transaminase; BCS, bovine
calf serum; OVA
 
I
 
, OVA peptide SIINFEKL restricted to H-2K
 
b
 
; OVA
 
II
 
,
OVA peptide ISQAVHAAHAEINEAGR restricted to I-A
 
d
 
. 
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ics and consequences of CD8
 
1
 
 versus CD4
 
1
 
 T cell migra-
tion to the liver after antigen stimulation, two TCR trans-
genic mouse models were used, both of which recognize
chicken OVA. T cells from OT-1 mice recognize OVA
peptide 257–264 (OVA
 
I
 
) restricted to class I MHC, K
 
b
 
 (17),
whereas those from DO.11.10 mice recognize OVA peptide
323–339 (OVA
 
II
 
) in the context of class II MHC, I-A
 
d
 
 (16).
A concentration range of OVA peptide was initially ex-
amined to determine what dose in vivo would produce a
moderate increase of lymphocyte number in peripheral
lymphoid tissues. In the case of OT-1 mice, 250 
 
m
 
l of 10-
 
m
 
M
OVA
 
I
 
 produced only a slight increase in lymphoid number
(data not shown), whereas 100-
 
m
 
M OVA
 
I
 
 produced a
more substantial and reproducible increase and was conse-
quently used in subsequent studies. A single administration
of 250 
 
m
 
l of 100-
 
m
 
M OVA
 
I
 
 produced an abrupt decrease
in thymocyte numbers by day 2, concomitant with a mod-
erate twofold increase in lymph node cell numbers and lit-
tle change in the number of splenocytes (Table 1, 
 
Exp. no.
1
 
). During this period, the number of liver lymphocytes
rose from a mean of 0.8 to 5.6 
 
3 
 
10
 
6
 
. Less pronounced ef-
fects were observed with the lower affinity OVA peptide
variants E1 and R4. The affinities of the OT-1 TCR for
the E1/K
 
b
 
 complex (
 
K
 
d
 
 
 
5 
 
22.6 
 
m
 
M) and R4–K
 
b
 
 complex
(
 
K
 
d
 
 
 
5 
 
57.1 mM) are reduced 3.5- and 8.8-fold, respec-
tively, compared with native OVAI (Kd 5 6.5 mM) (20).
Although a single dose of E1 and R4 produced a slight de-
crease in thymocyte numbers on day 2, there was other-
wise only a modest increase in the size of peripheral lym-
phoid cell numbers by day 2, but no increase in the
number of liver lymphocytes (Table 1, Exp. no. 1). This
was also true even when E1 and R4 were administered
three times at 24-h intervals (Table 1, Exp. no. 3).
Two doses of OVAI resulted in a pronounced decrease of
thymus size by day 2 and an increase in the number of lymph
node cells and splenocytes, which peaked on day 3 (Table 1,
Exp. no. 2). At the same time, there was a particular increase
in the number of liver lymphocytes, which peaked on day 2.
When administered at three 24-h intervals, OVAI produced
a profound increase (to 27 3 106) in the number of liver
lymphocytes (Table 1, Exp. no. 3), but this dose also resulted
in severe hepatic damage (see below). Thus, two 250-ml ad-
Table 1. Kinetics of Lymphocyte Cell Numbers after Administration of OVAI Peptide Variants to Class I–restricted (OT-1) OVA-specific 
TCR Transgenic Mice
Exp. no. Antigen No. of doses
Day after
antigen
Cell number 3 106 (6 SD)
Thymus Lymph node Spleen Liver
1 PBS 1 2 24.0 (9.1) 3.9 (1.3) 16.6 (6.5) 0.8 (0.14)
OVAI 1 1 9.6 (3.4) 7.2 (3.9) 23.4 (10.4) 1.9 (0.6)
OVAI 1 2 4.1 (2.7) 8.0 (7.9) 21.7 (23.6) 5.6 (0.14)
E1 1 1 32.3 (2.2) 4.7 (0.99) 25.2 (10.2) 0.73 (0.59)
E1 1 2 11.3 (6.8) 5.5 (4.1) 31.9 (13.1) 1.2 (0.25)
R4 1 1 12.3 (1.02) 3.9 (5.9) 47.6 (14.2) 0.7
R4 1 2 17.6 5.4 34.4 0.6
2 PBS 2 3 21.3 (4.4) 3.7 (1.9) 57.7 (4.9) 1.4 (0.1)
OVAI 2 2 1.8 (0.1) 7.7 (1.7) 67.3 (22.2) 11.2 (1.8)
OVAI 2 3 4.5 (4.3) 11.0 (7.7) 80.2 (54.6) 6.3 (1.7)
OVAI 2 5 (1 died) 1.3 (1.5) 1.6 (0.8) 68.8 (92.3) 2.0 (0.1)
3 PBS 3 2 27.7 (2.7) 4.2 (0.84) 45.6 (0.57) 3.1 (0.99)
OVAI 3 2 2.0 (0.89) 4.6 (0.77) 37 (8.3) 26.4 (5.5)
OVAI 3 3 0.75 (0.35) 6.5 (0.71) 14.9 (13.6) 27.8 (15.2)
OVAI 3 5 (2 died) 3.2 1.2 13.6 9.5
OVAI 3 7 0.2 (0.5) 0.08 (0.04) 5.2 (3.4) 0.8 (1.2)
E1 3 5 18 2.8 32.8 1.5
R4 3 5 19.8 4.4 44.4 3.4
Female OT-1 mice (aged 10 wk in exp. no. 1, 18 wk in exp. no. 2, and 15 wk in exp. no. 3) received either 250 ml of PBS or 250 ml intraperito-
neally of a 100-mM solution in PBS of the indicated peptide once daily for a total of one, two, or three doses. Peptides included either high affinity
native OVAI 257-264 (SIINFEKL, Kd 5 6.5 mM), or single amino acid variants of lower affinity, E1 (EIINFEKL, Kd 5 22.6 mM) or R4 (SIIR-
FEKL, Kd 5 57.1 mM). Mice were examined on the indicated days after the last injection. Three mice were used for each condition, with the excep-
tion of exp. no. 3 where single mice received E1 or R4. Lymph node cell numbers reflect total yields from four nodes.1150 Selective CD81 T Cell–induced Liver Damage
ministrations of 100-mM OVAI were optimal for producing
moderate expansion of peripheral lymphoid cell numbers
and an increase in liver infiltration by lymphocytes.
Compared with the effects of OVAI in OT-1 mice, the
same doses of OVAII administered to DO.11.10 mice
yielded a similar loss of thymocytes and initial expansion of
peripheral lymphoid tissues, but there was a somewhat less
profound loss of lymphocytes at later time points (Tables 1
and 2 and Fig. 1). The DO.11.10 TCR binds OVAII/I-Ad
with an affinity of 31 mM (21). After OVA administration
in both OT-1 and DO.11.10 mice, there was an initial ex-
pansion of lymph node cell number on days 2 and 3. After
this, the rate and extent of decline in cell numbers was
more pronounced in OT-1 mice. Thus, by day 5, lymph
node and splenocyte cell numbers in OT-1 mice receiving
OVAI were the same as or considerably below those of
control OT-1 mice, whereas peripheral lymphocyte cell
numbers in DO.11.10 mice were often still above those of
control mice. Similar differences were observed with three
doses of the respective native OVA peptides (Tables 1 and 2).
Paralleling the temporal differences in lymphocyte loss be-
tween OT-1 and DO.11.10 mice after administration of their
respective OVA peptides, both the kinetics and magnitude of
lymphocyte accumulation in the liver were greater in the
OT-1 mice. As mentioned above and shown in Table 1, after
two doses of OVAI, OT-1 liver lymphocyte numbers in-
creased from a control of 1.4 3 106 to 11.2 3 106 on day 2,
and after three doses of OVAI this increased further to 27 3
106 on days 2 and 3. Thereafter, the degree of lymphocyte in-
filtration rapidly declined. In contrast, equivalent doses of
OVAII in DO.11.10 mice produced only modest increases in
liver lymphocytes on day 2 and these continued to increase
throughout days 5–7, although they never reached the magni-
tude seen in OT-1 mice (Table 2). The greater liver lympho-
cyte infiltrate in OT-1 mice was paralleled by an increased
mortality in this group. At two doses, one out of nine OVAI-
treated OT-1 mice died on day 5, whereas at three doses, two
out of nine mice died, also on day 5. No DO.11.10 mice died
from OVAII administration at any of the doses studied.
Cell Size Changes and Induction of CD42CD82B2201
Phenotype in OT-1 T Lymphocytes after OVAI Administra-
tion. In addition to the changes in the number of lym-
phocytes after administration of OVAI, there were also sub-
Figure 1. OVA antigen induces greater increase of liver lymphocytes
in OT-1 than in DO.11.10 mice. OT-1 or DO.11.10 mice from experi-
ment no. 2 received two doses of PBS or, respectively, OVAI and OVAII
at 24-h intervals. Total lymphocyte numbers were determined for each
organ on the day indicated after the last injection.
Table 2. Kinetics of Lymphocyte Cell Numbers after Administration of OVAII Peptide to Class II–restricted (DO.11.10) OVA-specific TCR 
Transgenic Mice
Exp. no. Antigen No. of doses
Day after
antigen
Cell number 3 106 (6 SD)
Thymus Lymph node Spleen Liver
1 PBS 1 2 81.1 6.8 87.2 2.4
OVAII 1 1 28.3 24.8 72.1 2.6
OVAII 1 2 30.3 14.8 63.6 6.8
2 PBS 2 2 77.5 (4.9) 6.2 (0.85) 82.2 (7.1) 2.0 (0.64)
OVAII 3 2 17.8 (0.85) 7.9 (3.0) 104 (19.8) 4.2 (2.4)
OVAII 3 5 7.8 (2.5) 3.5 (0.14) 101 (7.8) 4.0 (1.4)
3 PBS 3 3 74.5 5.6 77.2 1.5
OVAII 3 3 21.6 35.6 76 4.8
OVAII 3 5 16.8 14.1 98.3 6.1
OVAII 3 7 30.4 10.4 52.2 6.4
18–20-wk-old DO.11.10 mice received either 250 ml of PBS or 250 ml intraperitoneally of a 100-mM solution in PBS of OVAII 323–339
(ISQAVHAAHAEINEAGR) once daily for a total of one, two, or three doses. Mice were examined on the indicated days after the last injection.
Lymph node cell numbers reflect the total from four nodes. Single mice were used for each condition in exp. no. 1 and no. 3, and two mice per con-
dition for exp. no. 2.1151 Russell et al.
stantial changes in their morphology and phenotype. We
(10) and others (22) have considered that the CD42CD82
phenotype for T cells reflects those that have received a
high intensity TCR signal and are prone toward apoptosis.
A useful additional marker for dying T cells is B220, the
high molecular weight B cell isoform of CD45 (4). Thus,
expression of B220 and loss of CD4 and CD8 were used
along with cell size and Annexin V staining of apoptosis to
determine the phenotype and fate of lymphocytes after
treatment of OT-1 and DO.11.10 mice with OVA.
The shifts in cell size and phenotype after administration
of OVA peptides were also more dramatic in the OT-1
mice than in DO.11.10 mice. Although most of the TCR
transgenic Va21 cells in lymphoid tissues of control OT-1
mice were CD81, after OVAI there was a large but tran-
sient increase in the proportion of peripheral CD42CD82
Va21 cells. A striking shift from CD81 to CD42CD82
could be seen as soon as 1 d after administration of only the
high affinity OVAI peptide. As shown in Fig. 2, the low
and moderate affinity OVAI variants, R4 and E1, respec-
tively, produced little or no substantial change from PBS-
injected control mice in the phenotypic composition of the
lymph nodes, which were predominantly CD81 and mani-
fested only 8–9% surface B220. However, within 24 h of a
single dose of OVAI there was a decrease in the proportion
of CD81 cells, from 60% with PBS to 28% with OVAI.
Accompanying this was a reciprocal increase in the propor-
tion of CD42CD82 cells, from 35% with PBS to 69% with
OVAI, 45% of which were Va21 (Fig. 2). These pheno-
typic shifts were confirmed by absolute numbers. The
number of CD81Va21 cells decreased only after treatment
with OVAI. The number of CD42CD82Va21 lymph
node cells did not change with R4 and increased nearly
twofold with E1, whereas with OVAI this subset increased
fourfold. These changes in phenotype and cell number
were very consistent in three separate experiments. In addi-
tion to the induction of CD42CD82Va21 cells with
OVAI, the residual CD81 cells after OVAI treatment now
expressed increased amounts of B220 (24%). B220 expres-
sion by the CD42CD82Va21 subset was already signifi-
cant before antigen exposure (62–78%) and did not in-
crease any further after OVAI administration (Fig. 2). This
may reflect the fact that the CD42CD82 T cells in normal
mice have also arisen by a high intensity TCR signal from
endogenous or environmental antigens.
Various sized lymphoid populations appeared in rapid
succession after two doses of OVAI to OT-1 mice, as
shown for lymph node cells in Fig. 3. On day 2 a blast pop-
ulation was observed that was enriched in the proportion of
CD42CD82Va21 cells compared with control OT-1 mice.
This increase occurred at the expense of the CD81 subset,
which on day 2 diminished from 63 to 43%, but at the
same time manifested increased B220 expression (34%)
compared with control mice (17%) (Fig. 3 A). Concomi-
tantly, a subpopulation of small cells gradually increased
during the 5 d after administration of OVAI. As shown in
Fig. 3 B, these small cells were considerably enriched in the
proportion of CD42CD82B2201Va21 cells, even in PBS-
treated control mice. Furthermore, the minor CD81 subset
also expressed more B220 than was seen in the blast cells.
These morphologic and phenotypic changes corresponded
to an initial expansion in peripheral lymphoid cell numbers
Figure 2. Induction of CD42
CD82Va21 and CD81B2201
phenotype only by high affinity
OVAI peptide. OT-1 mice,
three per group, received a single
injection of the indicated peptide
or PBS. OVAI confers a high af-
finity (Kd 5 6.5 mM) interaction
with the OT-1 TCR when
complexed with Kb. R4 and E1
are OVAI variants that manifest
affinities of 57.1 and 22.6 mM,
respectively. On day 1 after in-
jections, lymph node cells from
each group were pooled and an-
alyzed for expression of CD4,
CD8, Va2, and B220. Numbers
in quadrants indicate the per-
centage of positive cells. The
forward and side scatter histo-
grams at the left show that the
gates set for this analysis were
uniform and did not include
small dying cells. Numbers in pa-
rentheses represent the percent-
age of Va21 cells that express
B220. The right hand column
displays absolute numbers of
CD81Va21 and CD42CD82
Va21 cells. The findings are rep-
resentative of three experiments.1152 Selective CD81 T Cell–induced Liver Damage
by day 2 followed by a rapid decline by day 5 in OT-1
mice that had received OVAI (Fig. 4 A). Throughout this
period there was an increase in the expression of B220
by the CD81 subset in thymus, lymph node, and spleen
(Fig. 4 B). In contrast to OT-1 mice, the appearance of
CD42CD82 B2201 T cells did not occur in DO.11.10
mice at the same dose of OVAII (Fig. 5). In fact, the abso-
lute number of CD42CD82KJ1-261 cells often decreased
with OVAII, whereas the number of CD41 lymph node
cells increased. Even at a 100-fold higher dose of OVAII
there was still no significant induction of B220 expression
by T cells, nor of CD42CD82 T cells (data not shown).
Liver Lymphocyte Phenotype. By contrast with other
lymphoid tissues, after OVAI treatment of OT-1 mice the
liver lymphocytes contained an initial dramatic increase in
the proportion and absolute number of CD81Va21 and
CD42CD82Va21 cells (Fig. 4 A). This caused the ratio of
CD42CD82Va21 to CD81Va21 cells to decrease rather
than increase as observed in the lymph nodes (compare
Figs. 2 and 6). However, by day 5 the proportion of CD81
cells had decreased to nearly their initial levels, with a
somewhat slower decline in the proportion of CD42CD82
Va21 cells. In addition, after OVAI administration the
liver lymphocytes did not manifest significant B220
expression in either the CD81 or CD42CD82 subsets over
the 5-d course of the experiment. These findings suggested
that migration of lymphocytes to the liver was a selective
process in OT-1 mice, initially of activated CD81 cells;
however, they may have changed their phenotype to
CD42CD82 within the liver.
Annexin V staining confirmed that lymphocytes in the
liver were undergoing increased apoptosis. Fig. 7 A displays
Annexin V staining from experiment no. 3 and illustrates
that the resident CD81 liver lymphocytes in OT-1 mice
contained a higher proportion of Annexin V1 cells (57.1%)
than either lymph node (13.8%) or spleen (11.9%, data not
shown). After OVAI administration, there was a significant
increase on day 2 of Annexin V1 CD81 cells in lymph node
(42.8%) and spleen (34.4%, data not shown), which de-
creased only partially by day 5. In contrast, the liver lympho-
cytes maintained an already high proportion of Annexin V1
CD81 cells (58.8%). By day 5, the Annexin V1 subset of
Figure 3. OVAI induces blast formation of OT-1 T cells followed by
the appearance of small T cells that express B220 and are enriched for a
CD42CD82Va21 phenotype. OT-1 mice received two injections of
OVAI or PBS in experiment no. 2. Lymph node cells were analyzed on
the indicated days after the last injection. (A) An initial blast population
appears on day 2 following OVAI which then becomes a smaller transi-
tion cell population over the next 3 d. Surface phenotype is based on the
large and moderate sized cells as shown by the enclosed gate. (B) The small sized population of lymphocytes is enriched for CD42CD82Va21B2201
cells. OVAI administration also increased the proportion of CD81 cells expressing B220.
Figure 4. Cell counts and percentage of B220 expression by the CD81Va21 and CD42CD82Va21 subsets of T cells from OT-1 mice after two doses
of OVAI. Analysis is based on the same mice as used in experiment no. 2 in Fig. 1 and phenotypes were determined on the living cells based on flow cy-
tometric size gates. Tissues were pooled from three OT-1 mice per group. (A) Actual lymphocyte counts of subsets in various organs. (B) Percentage of
cells in the indicated subset that expressed B220.1153 Russell et al.
CD81 liver lymphocytes had decreased to levels seen in the
periphery, and were clearly less than was observed in liver
lymphocytes from control mice. As before, DO.11.10 mice
demonstrated less evidence of lymphocyte apoptosis after
OVAII (Fig. 7 B). Although DO.11.10 liver lymphocytes re-
vealed more apoptosis than lymph node cells from the same
mice, these levels did not approach those seen in OT-1
mice. The findings were similar in two other experiments.
Infiltrating CD81 Liver Lymphocytes Induce Hepatocyte
Death. Similar to the more profound influx of liver lym-
phocytes in OT-1 mice versus DO.11.10 mice after OVA
treatment, serum levels of the hepatocyte enzyme aspartate
transaminase (AST) rose dramatically in OT-1 mice, but
not at all in DO.11.10 mice. As shown in Table 3, AST el-
evation was maximal and statistically significant on day 2 in
OT-1 mice (P 5 0.030), which corresponded to the time
of greatest numbers of liver lymphocytes.
Because serum AST elevation parallels hepatocyte injury,
liver histology was examined before and after OVA adminis-
tration to assess the degree of hepatocyte damage. Fig. 8
shows hematoxylin and eosin–stained liver sections from
OT-1 mice (left) and DO.11.10 mice (right). Livers from
nontransgenic C57BL/6 mice that received OVAI peptide
(Fig. 8 A) and from BALB/c mice that received OVAII (Fig.
8 F) showed a normal morphology of hepatocytes with few
lymphocytes in the liver sinusoids. Similarly, PBS adminis-
tration to OT-1 mice (Fig. 8 B) and DO.11.10 mice (Fig. 8
G) had similar normal appearances. However, there was an
intense infiltration of liver lymphocytes over the 5 d after
OVAI administration to OT-1 mice. On day 2 there was a
prominent infiltrate that was confined to the periportal re-
gion (Fig. 8 C). By day 3 this had progressed to an intense
pansinusoidal infiltration of lymphocytes accompanied by
extensive hepatocyte damage (Fig. 8 D). Thus, the peak of
observed hepatocyte damage histologically occurred 24 h af-
ter the peak serum AST elevations. By day 5 the lymphocyte
infiltrate was largely resolved (Fig. 8 E). Accompanying this
recovery was the appearance of massive levels of hepatocyte
mitosis (Fig. 8, E and J). Although DO.11.10 mice also man-
ifested periportal lymphocytic infiltrates on day 2 after
OVAII (Fig. 8 H), these quickly dissipated as liver lympho-
cytes became more loosely scattered throughout the liver on
days 3–5 (Fig. 8 I). Throughout this process there was no ev-
idence of hepatocyte injury in DO.11.10 mice.
Figure 5. OVAII does not
induce B220 expression or
CD42CD82 phenotype by re-
sponding CD41 cells from
DO.11.10 mice. DO.11.10 mice
received OVAII injections and
lymph node cells (top) or liver
lymphocytes (bottom) were exam-
ined for expression of CD4, CD8,
B220, and clonotype TCR using
antibody KJ1-26. The right col-
umn indicates the absolute num-
bers of KJ1-261 cells that were
CD41 or CD42CD82. Pheno-
types were based on gates set for
living cells as in Fig. 2.
Figure 6. Some resident liver T lymphocytes in OT-1 mice express
B220, but after OVAI administration the initial influx is of CD81 cells that
lack B220. OT-1 mice received two injections of OVAI in experiment no.
2 and liver lymphocytes were isolated on the indicated days after the last in-
jection. The forward and side scatter histograms at the left show that the
gates set for this analysis were uniform and did not include small dying cells.1154 Selective CD81 T Cell–induced Liver Damage
Discussion
Our findings support a model in which the liver is a des-
tination for lymphocytes that have been activated by a high
intensity TCR signal, many of which are destined to un-
dergo apoptosis. Although lymphocytes may not be ac-
tively undergoing apoptosis as they enter the liver, given
the generally higher levels of Annexin V staining of intra-
hepatic lymphocytes compared with peripheral lymphoid
tissues, it is most likely that a considerable portion are tar-
geted for apoptosis after entry. In this study, this process
appeared to be more dynamic for CD81 than CD41 T
cells. Furthermore, the entry of activated CD81 lympho-
cytes into intrahepatic sinusoids was responsible for exten-
sive hepatocyte death.
The notion that “damaged” lymphocytes might not traffic
normally to peripheral lymphoid tissues but might rather
migrate to the liver has been appreciated for some time.
Treatment of lymphocytes with trypsin (23) or glycosidases
(24) before intravenous infusion prevented the cells from
circulating normally. After neuraminidase treatment of lym-
phocytes to remove terminal sialic acid residues, the cells
selectively migrated to the liver (25). Conceivably, recogni-
tion of such altered lymphocytes might occur via the
asialoglycoprotein receptor expressed by hepatocytes (26).
One of the early events in apoptosis is the expression of sur-
face phosphatidylserine residues on the outer surface of the
plasma membrane, which are normally confined to the inner
leaflet (19). Receptors for phosphatidylserine are expressed
by macrophages such as the Kupffer cells in the liver (27).
This might further enhance the tendency of T cells that are
targeted for apoptosis to migrate to the liver. It is conceivable
that the abrupt increase in OT-1 liver lymphocytes follow-
ing administration of OVAI might represent clonal expan-
sion of resident liver lymphocytes rather than migration to
the liver. However, this is unlikely as the fold increase of liver
lymphocytes vastly surpassed that of peripheral lymphocytes.
Figure 7. Liver lymphocytes and lymph node cells are undergoing in-
creased apoptosis in OT-1 mice compared with DO.11.10 mice. Mice
are from experiment no. 3 and received three doses of PBS, OVAI (OT-1
mice), or OVAII (DO.11.10 mice) at 24-h intervals. Lymphoid cells were
isolated at the indicated time points and stained with Annexin V and ei-
ther anti-CD8 (for OT-1 mice) or anti-CD4 (for DO.11.10 mice). Anal-
ysis is gated on CD81 cells from OT-1 mice (A) or on CD41 cells from
DO.11.10 mice (B).
Figure 8. Infiltration of lymphocytes into the liver and resulting hepatocyte damage after OVA administration are both more pronounced in OT-1
mice than DO.11.10 mice. Livers were taken from mice of experiment no. 2 that had received two doses of OVA and were stained with hematoxylin
and eosin. Original magnification is 3160 except for J, which is 31,000. Administration of OVAI to nontransgenic C57BL/6 mice (A) and OVAII to
nontransgenic BALB/c mice (F) yielded no influx of liver lymphocytes and no hepatocyte damage. Similarly, PBS administration to OT-1 mice (B) or
DO.11.10 mice (G) also produced no infiltrates. Beginning on day 2 after administration of OVAI to OT-1 mice or OVAII to DO.11.10 mice, periportal
lymphocytic infiltrates were observed in both mice but were more intense in OT-1 (C) than DO.11.10 mice (H). By day 3 a massive lymphocytic infil-
trate is observed throughout the livers of only OT-1 mice with extensive hepatocyte damage (D). By day 5 the lymphocytic infiltrate in OT-1 livers is re-
solved (E) and in its wake is observed a dramatic burst of hepatocyte mitotic activity, shown magnified in J. By contrast, DO.11.10 mice never manifested
extensive liver sinusoidal lymphocytes as infiltrates were completely gone by day 5 without any evidence of hepatocyte damage or mitotic rebound (I).
Table 3. Elevation of Serum AST after Activation of OT-1 
CD81 Cells
Mouse strain Antigen
Days after
antigen
Mean (6 SD) serum
AST
 U/liter
OT-1 PBS 2 172 (84.4)
OVAI 2 586 (153) [P 5 0.030]
OVAI 3 197 (82.6)
OVAI 5 174 (5.7)
C57BL/6 OVAI 2 119 (38.9)
DO.11.10 PBS 2 126 (55.2)
OVAII 2 115 (34.6)
OVAII 5 97.5 (14.8)
Three OT-1 mice and two DO.11.10 mice received, respectively,
OVAI and OVAII administered as two 250 ml intraperitoneal doses of a
100-mM solution at 24-h intervals. As a control for nonspecific effects
of the OVAI peptide, two nontransgenic C57BL/6 mice received the
same dose of OVAI. Serum AST levels were determined at the indi-
cated times after administration of antigen. The only group with signifi-
cantly elevated AST levels compared to PBS control mice was day 2
OT-1 mice (P 5 0.030, paired Student’s t test).1155 Russell et al.1156 Selective CD81 T Cell–induced Liver Damage
Furthermore, liver lymphocytes were not observed to be in
the G2/S phase of the cell cycle by propidium iodide analysis
(Russell, J.Q., unpublished observations). Thus, it is more
likely that the activated lymphocytes migrated to the liver.
In this study, CD81 T cells from the class I MHC–
restricted TCR transgenic OT-1 mouse manifested a con-
siderably more dramatic influx into the liver with resulting
hepatocyte damage after receiving OVAI than did CD41 T
cells from DO.11.10 mice after an equivalent dose of OVAII.
This was paralleled by a greater tendency for OT-1 CD81
T cells in lymph node and spleen to acquire B220 expression
and to manifest a CD42CD82 phenotype than was demon-
strated by DO.11.10 CD41 cells. These findings are in partial
agreement with those of Huang et al. (4), which showed
that after exposure to a class I MHC–restricted antigen, a por-
tion of the responding peripheral CD81 T lymphocytes be-
came CD42CD82B2201. However, that study also observed
that the T cells that migrated to the liver after antigen ex-
posure were predominantly of the CD42CD82B2201 phe-
notype. In contrast, we observed an influx of primarily
CD81 cells with a smaller proportion of CD42CD82 T cells,
although the absolute numbers of the latter population in
the liver did increase considerably. The difference in these
two systems may reflect that in OT-1 mice the large pro-
portion of CD42CD82B2201 T cells generated in the
lymph nodes and spleen with OVA never reached the liver
and died in situ or en route to the liver.
We (10) and others (22) have previously suggested that
the CD42CD82 T cell phenotype reflects high intensity
TCR signaling and a tendency to undergo apoptosis. This
would be consistent with the findings that in OT-1 mice
only the high affinity OVAI peptide, and not the lower affin-
ity E1 and R4 peptide variants, induced CD42CD82 Va21
cells and concomitant liver damage. It is possible that the
higher intensity signaling by OT-1 T cells was unique to this
system and not applicable to CD81 versus CD41 T cells in
general. In this regard, the OT-1 TCR has an affinity of 6.5
mM for OVAI/Kb (20), whereas the affinity of the DO.11.10
TCR for OVAII/I-Ad is 31 mM (21). However, in other
studies using class I– and class II–restricted TCR transgenic
mice different from those used in this study, the findings also
showed that the class I–restricted CD81 T cells manifested a
much greater influx into the liver as well as a higher propor-
tion of CD42CD82B2201 T cells (Crispe, I.N., personal
communication, and reference 4). Furthermore, as normal
mice age the liver accumulates a greater proportion of CD81
and CD42CD82 T cells than of CD41 T cells (6). This may
reflect merely an increased tendency of CD81 T cells to traf-
fic to the liver after activation. Alternatively, the collective
findings also agree with other studies of thymocyte develop-
ment, suggesting that on average CD81 T cells may receive
higher intensity signals than do CD41 cells (22).
It has been previously appreciated that infiltration of the
liver by Con A–activated lymphocytes produces collateral
liver damage (28). As such, that study and this may represent
models of autoimmune hepatitis in which T lymphocytes
become antigen activated in lymphoid organs and then
migrate to the liver and cause hepatocyte apoptosis. Hepato-
cytes may be merely innocent bystanders in this system, hav-
ing little if anything to do with actual antigen presentation.
Hepatocytes express high levels of Fas and are highly suscep-
tible to apoptosis induced by in vivo administration of anti-
Fas antibody (29). However, in the Con A–induced liver
injury model, it appears that perforin plays a more prominent
role than Fas-mediated cell death (30). Studies are in progress
to examine this issue in OT-1/lpr mice. This mechanism of
lymphocyte-mediated tissue injury might also apply to other
target organs and manifest itself as idiopathic autoimmune
damage. In this system, antigen presentation by the target
organ may not be necessary for either the trafficking of
lymphocytes to the organ or the subsequent tissue injury
induced by infiltrating lymphocytes. We (Russell, J.Q., un-
published observations) and others (31) have observed that
antigen-activated T cells also traffic to the lung and kidneys
and we are examining the degree of tissue injury that results
at these sites. This model might also serve to explain the liver
dysfunction that is often observed after situations where the
immune system has been strongly activated, such as by a
superantigen in Kawasaki disease (32, 33).
Beyond the parallels with autoimmune hepatitis, our
findings may also have implications for normal liver homeo-
stasis. The resident liver lymphocytes that are observed be-
fore intentional antigen challenge may have also migrated to
the liver after activation by endogenous or environmental
antigens. This constant low level influx of activated lym-
phocytes may result in a continual minimal degree of hepa-
tocyte apoptosis. In this regard, it is interesting to note that
liver enlargement due to actual increase in hepatocyte mass
has been observed in Fas-deficient mice (34).
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